23.10.2012 Views

SYMPOSIA

SYMPOSIA

SYMPOSIA

SHOW MORE
SHOW LESS

You also want an ePaper? Increase the reach of your titles

YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.

from triage to discharge.<br />

Key words: Crisis team, referral pathways, community care<br />

Bulletin of Clinical Psychopharmacology 2011;21(Suppl. 2):S128-9<br />

Bulletin of Clinical Psychopharmacology, Vol: 21, Supplement: 2, 2011 - www.psikofarmakoloji.org<br />

Poster Presentations<br />

[PP-014 Ref. No: 122<br />

Fluanxol and haloperidol efficacy evaluation in treatment of schizophrenic patients<br />

Elena Valzdorf<br />

Irkutsk Regional Psychoneurologic Dispensary, Irkutsk, Russia.<br />

E-mail: elenavalzdorf@yandex.ru<br />

Objective: The purpose of the research was to study the efficacy of Fluanxol in the treatment of schizophrenic patients compared with haloperidol.<br />

Method: Research subjects were 23 paroxysmal progredient schizophrenia patients, who were stationary examined. There were 18 men<br />

and 5 women among them, 6 patients of 16 to 20 years of age and 17 patients aged between 20 to 40 years.<br />

A clinical-psychopathological research method with a psychopharmacological approach was used.<br />

Results: Three groups of patients were picked out. The first group of 9 patients included patients with an acute and subacute exacerbation,<br />

Kandinski-Klerambo syndrome, acute sensitive delusions of grandeur, of influence, of persecution with imperative pseudo hallucinations,<br />

and open thought symptoms.<br />

The second group of 4 cases included patients with paraphrenia acute exacerbations, expansive delusions, and auditory pseudo<br />

hallucinations with oneric inclusions.<br />

In both groups the therapy began with traditional neuroleptics. Haloperidol depot 5 mg was prescribed intramuscularly once every 2<br />

weeks, but haloperidol intravenously from 5 to 10 mg a day. During 7-10 days of treatment, productive psychotic symptoms were reduced<br />

only through intensity in order to change preparation closed to atypical antipsychotic drug. So Fluanxol depot from 10-20 mg was<br />

prescribed intramuscularly once every 2 weeks and at the same time patients took it from 3 to 10 mg twice a day inside. During Fluanxol<br />

therapy, psychotic symptoms were reduced after 5-7 days of treatment.<br />

The third group of 10 people included less progredient schizophrenia patients with neurosis-like negative symptomatology. Haloperidol<br />

from, 1.5 to 5 mg a day inside for 3-4 weeks of treatment, didn’t have a positive effect on the negative symptoms. Fluanxol, from 1 to 3 mg<br />

twice a day inside for 7-12 days of treatment, caused a decrease in intensity or a complete reduction in negative symptomatology, so as<br />

mimics, mood, emotions were improved. This Fluanxol effect was shown by the two first groups having negative symptoms. Most patients<br />

took it without any corrector-preparation.<br />

Conclusion: Fluanxol is more effective in the treatment of schizophrenic patients.<br />

In comparison with haloperidol it decreased positive symptomatology more quickly, decreased or completely reduced negative<br />

symptoms and only in some cases caused drug side effects.<br />

Key words: Fluanxol, haloperidol, schizophrenia<br />

Bulletin of Clinical Psychopharmacology 2011;21(Suppl. 2):S129<br />

[PP-015] Ref. No: 241<br />

Anorexia nervosa and cannabis abuse: A case report<br />

Semra Karayılan, Atila Erol<br />

Department of Psychiatry, Sakarya University School of Medicine, Sakarya, Turkey<br />

E-mail: skryln@gmail.com<br />

Rates of comorbidity are higher in patients with eating disorders and also the number of comorbid disorders is numerous. Most<br />

comorbidities associated with eating disorders are mood disorders, anxiety disorders, personality disorders, and substance use disorders.<br />

According to past research, there is a high rate of comorbidity of alcohol-substance abuse and eating disorders. Although the majority of<br />

studies in this area are focused on the use of alcohol, studies that have identified an association between illegal substance use and eating<br />

disorders are also available. In a study in the USA, the use of cannabis with anorexia nervosa (AN) and bulimia nervosa (BN) disorders is<br />

reported to be 6-7%. In Turkey, in a study that investigated the comorbidity of eating disorders and substance use, the use of alcohol and<br />

cannabis was reported in cases of BN, but the use of psychoactive substances and cannabis was not established in cases of AN. Among<br />

S129

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!